Cathy Kelly
Senior Writer
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
PhRMA Willing To Contribute To Drug ‘Affordability’ – But Mum On How Much
PhRMA CEO Steven Ubl offers list of policy alternatives to drug pricing bills pending in the US Congress that he argues would stifle innovation; industry's plans, on the other hand, could produce "meaningful" legislation.
Beyond ICER: Arnold Foundation Wants To Dig Deeper On R&D And Pricing
Arnold Foundation VP Mark Miller explains how research into “what it costs to bring a drug to market” could supplement existing efforts to determine how prescription drug prices line up with value.
HHS Safe Harbor For Value-Based Drug Contracts May Be On Horizon
Drugs With ‘Unsupported Price Increases’ Add $5bn To US Spending – ICER
Pharmaceutical Research and Manufacturers of America describes report as “flawed” and designed to advance the “false narrative that spending on medicines in increasing.”
Drugs With ‘Unsupported Price Increases’ Add $5bn To US Spending – ICER
Pharmaceutical Research and Manufacturers of America describes report as “flawed” and designed to advance the “false narrative that spending on medicines in increasing.”
ICER Analyses Increasingly Guide US Price Negotiations, Payers Report
Nearly 65% of respondents reported ICER cost effectiveness reviews are 'likely' or 'extremely likely' to function as a benchmark in price negotiations with manufacturers, according to a recent survey.